Eosinophilic Pustular Folliculitis

Ryan Owen DO  
*Lehigh Valley Health Network, Ryan.Owen@lvhn.org*

Arthur C. Sosis MD  
*Lehigh Valley Health Network, Arthur.Sosis@lvhn.org*

Stephen M. Purcell DO  
*Lehigh Valley Health Network, Stephen.Purcell@lvhn.org*

Follow this and additional works at: [http://scholarlyworks.lvhn.org/medicine](http://scholarlyworks.lvhn.org/medicine)

Part of the [Dermatology Commons](http://scholarlyworks.lvhn.org/medicine), and the [Medical Sciences Commons](http://scholarlyworks.lvhn.org/medicine)

Published In/Presented At  

This Poster is brought to you for free and open access by LVHN Scholarly Works. It has been accepted for inclusion in LVHN Scholarly Works by an authorized administrator. For more information, please contact LibraryServices@lvhn.org.
Eosinophilic Pustular Folliculitis

Ryan Owen, DO, Arthur C. Sosis, MD, Tanya Ermolovich, DO and Stephen M. Purcell, DO
Lehigh Valley Health Network, Allentown, Pennsylvania

Case Presentations:

**Patient A**

**Patient:** 62-year-old Caucasian male

**History of Present Illness:** Patient presented with a 1-month history of a pruritic red rash on his face, neck, shoulders, and chest. The patient had already completed a course of azithromycin, IM trimcinolone, and oral prednisone with only minor improvement. He experienced initial improvement in his itching with a decrease in the number of skin lesions. One month after his initial presentation, he began to experience difficulty swallowing and fatigue. He experienced swollen tonsils with neck and axillary lymphadenopathy and was diagnosed with mantle cell lymphoma.

**Medical History/Surgical History:** Prostate cancer

**Current Medications:** Indomethacin, trimcinolone cream, and hyper CVAD rituximab chemotherapy

**Previous Treatments:** Azithromycin, IM trimcinolone, oral prednisone, and doxycycline

**Physical Examination:** Multiple pink to red folliculocentric papules and pustules admixed with edematous pink plaques scattered on the face, neck, shoulders, and back. Palms, soles, and oral mucosa were clear.

**Laboratory Data:** Serum HIV negative, CBC and CMP normal except as follows: eosinophilia 8% (0-4%)

**Studies:** CT: neck, chest, and abdomen demonstrated diffuse lymphadenopathy. PET/CT: extensive metabolically active lymphoma in multiple nodal groups above and below the diaphragm with lymphomatous involvement of spleen. Axillary LN Bx: Mantle cell lymphoma (CD4:CD8 1:1, CD45 (-), CD20 (+), CD5 (+)) and below the diaphragm with lymphomatous involvement of spleen. Axillary LN Bx: PET/CT: extensive metabolically active lymphoma in multiple nodal groups above and below the diaphragm with lymphomatous involvement of spleen.

**Biopsy:** Advanced Dermatology Associates, LTD

1A: Pink to red edematous papules with plaques on the face

1B: Closer view showing pustules on the right forehead

1C and 1D: H&E, Follicular spongiosis with perifollicular, interstitial, and periluminal lymphohistiocytic infiltration with numerous eosinophils

1E and 1F: H&E, Follicular spongiosis with peri- and parafollicular lymphohistiocytic infiltration with numerous eosinophils

2A and 2B: Hyperpigmented lichenified papules and nodules on the face, chest, and abdomen

2C and 2D: H&E, Follicular spongiosis with overlying focal epidermal spongiosis, superficial and mid dermal lymphohistiocytic inflammation, and abundant eosinophils

**Discussion:**

Eosinophilic pustular folliculitis (EPF) was originally described by Ofuji in 1965 with the first case presenting as folliculocentric pustules distributed on the face, torso, and arms of a Japanese female. Since the initial description, three distinct subtypes of EPF now exist. These types include the originally described classic variant seen in the Japanese population, an immunosuppressed (EPF-IS) variant, and a rare infantile form.

All three subtypes of EPF are more commonly seen in men compared to women. The classic form has a peak incidence between the third and fourth decades. It presents as recurrent follicular papules and pustules located on the face, trunk, or extremities and more rarely the palmpoplantar surfaces. Post inflammatory hyperpigmentation is common and leukocytosis with eosinophilia is seen in up to 35% of patients.

The IS subtype demonstrates intensely pruritic discrete erythematous follicular papules with palmpoplantar sparing, and infrequent annular or circinate plaque forms. Frequently with the IS-HIV form, CD4 cell counts are below 300 cells/μl (500-1200 cells/μl) and 25%-50% of patients have lymphopenia with eosinophilia. The IS-Heme form has been predominantly associated with hematologic malignancies including non-Hodgkin lymphoma, leukemia (ALL and ANLL), and myelodysplastic syndrome. For all of these cases except two, EPF followed bone marrow transplant, peripheral blood stem cell transplant, or chemotherapy initiation. To date, no reported cases of EPF presenting prior to the diagnosis of mantle cell lymphoma have been described.

Our patient cases represent variants of immunosuppression related eosinophilic pustular folliculitis. Patient A presented initially with EPF a month before being diagnosed with mantle cell lymphoma. Patient B had a more diffuse clinical presentation secondary to his underlying chronic immunosuppression.

Histopathologically, all three identified forms of EPF show acute and chronic lymphoepitheliocytic infiltrate concentrated at the follicular isthmus. In addition, scattered mononuclear cells, eosinophils, and neutrophils are typically found within the pilar outer root sheath, sebaceous glands, and ducts. Follicular mucinosis is seen in up to 40% of cases as well as follicular destruction.

The pathophysiology is believed to represent a Th2 predominant pathway (IL-3, IL-5, and IL-13) with eotaxin-3 expression, which promote eosinophil recruitment, inflammation, and tissue damage seen in EPF.

Multiple therapeutic modalities have been reported for the treatment of EPF. For all three types, moderate to high potency topical corticosteroids are considered first line of therapy while UVB phototherapy 2-3 times weekly remains the gold standard treatment. Indomethacin (50-75mg/ day) is first line treatment for classic EPF due to its ability to limit the chemoattraction of eosinophils. Other potential treatments include prednisone, psoralen plus UVA, cetirizine, metronidazole, minocycline, itraconazole, dapsone, systemic retinoids, topical tacrolimus, and topical permethrin.

References: